Aernoud Fiolet

259 Colchicine Attenuates Inflammation Beyond the Inflammasome Main figure. Serum protein level modulation after colchicine treatment. A, Eleven proteins with a significant median reduction >10% after colchicine treatment. B, Five proteins with a significant median increase >10% after colchicine treatment. All measurements are linear normalized protein expression levels (NPX) presented in a box plot with Tukey whiskers (1.5 interquartile range) and include all outliers as dots. Paired testing by sample t tests or Wilcoxon signed rank tests where applicable. Correction for multiple comparison using the Benjamini-Hochberg method with a false discovery rate (FDR) of 5%. *PFDR<0.001; **PFDR<0.01; ***PFDR<0.05. AZU1 indicates azurocidin; BL, levels at baseline; CCL17, C-C motif chemokine 17; CD40-L, CD40 ligand; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule-8; Colch, levels after colchicine treatment 0.5 mg daily for 1 month; FABP2, intestinal fatty acid-binding protein; FGF21, fibroblast growth factor 21; GP6, platelet glycoprotein VI; IGFBP-1, insulin-like growth factor-binding protein 1; IL-16, interleukin-16; MB, myoglobin; MPO, myeloperoxidase; NEMO, nuclear factor– κ B essential modulator; PRTN3, myeloblastin; SRC, proto-oncogene tyrosine-protein kinase Src; TMG2, protein-glutamine γ -glutamyltransferase 2; and U-PAR, urokinase plasminogen activator surface receptor.